SOD1 and amyotrophic lateral sclerosis: A recent study indicated that SOD1-ALS patients who received tofersen, an ASO which controls the degradation of SOD1 messenger RNA, measured a dose-dependent reduction from baseline in the total CSF SOD1 concentration of up to 36% after 12 weeks of treatment.30 Even though the safety and efficacy of tofersen are currently under investigation, the aforementioned study provides evidence that precision-medicine approaches using ASO could open the way to therapeutic interventions in ALS and potentially other neurodegenerative conditions.